Advertisement

Scientific Approaches for the Application of QbD Principles in Lyophilization Process Development

  • Vinay Radhakrishnan
  • Penny Davis
  • David Hiebert
Chapter
Part of the AAPS Advances in the Pharmaceutical Sciences Series book series (AAPS, volume 38)

Abstract

Lyophilization (or freeze drying) is an important manufacturing capability for delivering high-quality parenteral drug products. Significant lyophilization process knowledge based on established scientific fundamentals and understanding of the good freeze drying practice principles exists within the pharmaceutical industry. This cumulative scientific knowledge should be leveraged across the portfolio of both small and large molecules and serves as the basis to gain process and product understanding. By using the scientific principles of lyophilization, good freeze drying practices and existing product knowledge, a risk-based approach to process development will facilitate focused efforts to increase product and process understanding to decrease those risks and identify which parameters are critical for product quality. Ultimately, this approach driven by scientific principles results in the development of a robust control strategy for a given product. The process whereby this occurs is based on principles of Quality by Design (QbD) as defined in ICH Q8 (R2) Pharmaceutical Development. This chapter brings together the technical knowledge of the lyophilization process, well-established scientific lyophilization principles and elements of QbD to provide guidance on approaches to develop a robust manufacturing process and support a regulatory filing strategy for drug products, while maximizing the freedom to operate. While it incorporates QbD elements that align with ICH Q8 (R2), Q9, Q10, and Q11, the goal is to define a knowledge space based on robust scientific evidence and principles. Having this knowledge and data will provide the basis to justify the control strategy and lyophilization process description in the dossier that presents the critical product quality attributes and a process control strategy that is defined by the critical process parameters to ensure consistent product quality.

Keywords

Lyophilization Freeze-drying Quality by Design (QbD) Control strategy Risk assessment Process development Product temperature Quality control Process parameter Regulatory flexibility 

References

  1. 1.
    ICH Q8 (R2) Pharmaceutical development, Nov 2009.Google Scholar
  2. 2.
    ICH Q9 Quality risk management, Jun 2006.Google Scholar
  3. 3.
    ICH Q10 Pharmaceutical quality system, Apr 2009.Google Scholar
  4. 4.
    Mitchell M. Determining criticality-process parameters and quality attributes part I: criticality as a continuum. BioPharm Int. Dec 2013;26(12).Google Scholar
  5. 5.
    Mitchell M. Determining criticality—process parameters and quality attributes part II: design of experiments and data-driven criticality. BioPharm Int. Jan 2014;27(1).Google Scholar
  6. 6.
    ICH Q8, Q9, & Q10, Questions and answers, Appendix—Q&As from Training Sessions, July 2012.Google Scholar
  7. 7.
    A-Mab: a case study in bioprocess development, CMC biotech working, group, Ver 2.1, Oct 2009, http://c.ymcdn.com/sites/www.casss.org/resource/resmgr/imported/A-Mab_Case_Study_Version_2-1.pdf.
  8. 8.
    Nail S et al. Fundamentals of freeze-drying, pharmaceutical biotechnology. Feb 2002;14:281–360,  https://doi.org/10.1007/978-1-4615-0549-5_6.
  9. 9.
    Pikal MJ. Freeze drying, encyclopedia of pharmaceutical technology. 2006;1:1, 1807–33,  https://doi.org/10.1081/e-ept-100001712.
  10. 10.
    Tang X, Pikal MJ. Design of freeze-drying processes for pharmaceuticals: practical advice. Pharm Res. 2004;21(2):191–200.CrossRefPubMedGoogle Scholar
  11. 11.
    Shah A, Patel SM, Jameel F. Application of QbD principles for Lyophilized formulation development. In: Jameel F et al. (editors), Quality by Design for biopharmaceutical drug product development, AAPS advances in the pharmaceutical sciences series 18, Berlin: Springer; 2015.  https://doi.org/10.1007/978-1-4939-2316-8_8.Google Scholar
  12. 12.
    Pikal MJ. Use of laboratory data in freeze drying process design: heat and mass transfer coefficients and the computer simulation of freeze drying. J Pharm Sci Technol. 1985;39(3):115–39.Google Scholar
  13. 13.
    Gieseler H, Kramer T. Use of manometric temperature measurement (MTM) and SMART freeze dryer technology for development of an optimized freeze-drying cycle. J Pharm Sci. 2007;96(12):3402–18.CrossRefPubMedGoogle Scholar
  14. 14.
    Milton N, Pikal MJ. Evaluation of manometric temperature measurement as a method of monitoring product temperature during lyophilization. PDA J Pharm Sci Technol. 1997;51(1):7–16.PubMedGoogle Scholar
  15. 15.
    Patel SM, Doen T. Determination of end point of primary drying in freeze-drying process control. AAPS PharmSciTech. 2010;11(1):73–84.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Gieseler H, Kessler WJ. Evaluation of tunable diode laser absorption spectroscopy for in-process water vapor mass flux measurements during freeze drying. J Pharm Sci. 2007;96(7):1776–93.CrossRefPubMedGoogle Scholar
  17. 17.
    Nail S, et al. Recommended best practices for process monitoring instrumentation in pharmaceutical freeze drying—2017. AAPS PharmSciTech. 2017.  https://doi.org/10.1208/s12249-017-0733-1.CrossRefPubMedGoogle Scholar
  18. 18.
    Final Concept Paper—Q12: technical and regulatory considerations for pharmaceutical product lifecycle management, dated 28 July 2014.Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2018

Authors and Affiliations

  • Vinay Radhakrishnan
    • 1
  • Penny Davis
    • 2
  • David Hiebert
    • 3
  1. 1.Pfizer Inc.ChesterfieldUSA
  2. 2.Pfizer Inc.AndoverUSA
  3. 3.Pfizer IncPeapackUSA

Personalised recommendations